{"id":470,"date":"2026-02-05T13:01:32","date_gmt":"2026-02-05T19:01:32","guid":{"rendered":"https:\/\/portaltowellness.net\/?post_type=product&#038;p=470"},"modified":"2026-10-09T09:44:10","modified_gmt":"2026-10-09T14:44:10","slug":"semaglutide","status":"publish","type":"product","link":"https:\/\/portaltowellness.net\/es\/shop\/semaglutide\/","title":{"rendered":"Semaglutida \u2013 30mg\/vial \u2014 Solo para uso en investigaci\u00f3n"},"content":{"rendered":"<div class=\"notranslate\" translate=\"no\" data-wg-notranslate data-no-translation=\"\"><h2>Descripci\u00f3n general<\/h2>\n<style>.ptw-cmp-wrap{max-width:720px;margin:32px auto;font-family:-apple-system,BlinkMacSystemFont,\"Segoe UI\",Arial,sans-serif;color:#e2e8f0;}.ptw-cmp-wrap h3{font-size:20px;font-weight:700;color:#fff;margin-bottom:6px;}.ptw-cmp-wrap .ptw-cmp-sub{font-size:14px;color:#94a3b8;margin-bottom:16px;line-height:1.5;}.ptw-cmp-table{width:100%;border-collapse:collapse;background:#0d1f3c;border:1px solid #1e3a5f;border-radius:8px;overflow:hidden;font-size:14px;}.ptw-cmp-table th{background:#07111f;color:#64748b;text-transform:uppercase;letter-spacing:0.5px;font-size:11px;font-weight:700;padding:12px 14px;text-align:left;border-bottom:1px solid #1e3a5f;}.ptw-cmp-table td{padding:12px 14px;border-bottom:1px solid #1e3a5f;color:#e2e8f0;}.ptw-cmp-table tr:last-child td{border-bottom:none;}.ptw-cmp-table tr.ptw-highlight td{background:#112240;}.ptw-cmp-table .ptw-badge{display:inline-block;background:linear-gradient(135deg,#8A6500,#a67c00);color:#fff;font-size:10px;font-weight:700;letter-spacing:0.5px;text-transform:uppercase;padding:2px 8px;border-radius:10px;margin-left:6px;}.ptw-cmp-note{background:#112240;border:1px solid #1e3a5f;border-left:3px solid #7c3aed;border-radius:0 6px 6px 0;padding:14px 18px;margin-top:16px;font-size:13px;color:#94a3b8;line-height:1.6;}.ptw-cmp-note strong{color:#e2e8f0;}<\/style>\n<div class=\"ptw-cmp-wrap\">\n<h3>Compara los tama\u00f1os de Semaglutida<\/h3>\n<p class=\"ptw-cmp-sub\">Dos tama\u00f1os de vial del mismo compuesto.<\/p>\n<table class=\"ptw-cmp-table\">\n<tbody>\n<tr>\n<th>Producto<\/th>\n<th>Concentraci\u00f3n<\/th>\n<th>Precio<\/th>\n<th>Precio \/ mg<\/th>\n<\/tr>\n<tr>\n<td>Semaglutida 5mg<\/td>\n<td>5mg\/vial<\/td>\n<td>$24.00<\/td>\n<td>$4.80<\/td>\n<\/tr>\n<tr class=\"ptw-highlight\">\n<td>Semaglutida 30mg<span class=\"ptw-badge\">Menor $\/mg<\/span><\/td>\n<td>30mg\/vial<\/td>\n<td>$69.00<\/td>\n<td>$2.30<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p><!-- wp:html --><\/p>\n<style>.ptw-product-research-link{background:#f6f3ec;border:1px solid #e0d9c8;border-left:4px solid #8a7a4d;border-radius:8px;padding:14px 18px;margin:16px 0 20px;font-size:15px;}.ptw-product-research-link__label{display:block;font-size:11px;font-weight:700;letter-spacing:.08em;text-transform:uppercase;color:#8a7a4d;margin-bottom:6px;}.ptw-product-research-link__link{display:block;color:#1a2b4c;font-weight:600;text-decoration:underline;margin-top:3px;}<\/style>\n<p><!-- \/wp:html --><br \/>\n<!-- wp:html --><\/p>\n<p><!-- \/wp:html --><\/p>\n<p>La semaglutida es un agonista del receptor GLP-1 modificado sint\u00e9ticamente y uno de los compuestos m\u00e1s ampliamente caracterizados en la literatura publicada sobre farmacolog\u00eda de incretinas. Desarrollada originalmente como un an\u00e1logo de acci\u00f3n prolongada del p\u00e9ptido similar al glucag\u00f3n tipo 1 (GLP-1), la semaglutida ha acumulado un voluminoso conjunto de datos de farmacolog\u00eda precl\u00ednica y cl\u00ednica en los \u00e1mbitos de investigaci\u00f3n metab\u00f3lica, cardiovascular y neurol\u00f3gica, convirti\u00e9ndose en un compuesto ampliamente referenciado en estudios de biolog\u00eda del receptor GLP-1.<\/p>\n<h2>Qu\u00e9 es<\/h2>\n<p>La semaglutida es un an\u00e1logo sint\u00e9tico de 31 amino\u00e1cidos del GLP-1(7-37) humano que presenta tres modificaciones estructurales clave: una sustituci\u00f3n Aib en la posici\u00f3n 8 para conferir resistencia a la DPP-IV, una sustituci\u00f3n de lisina por arginina en la posici\u00f3n 34, y una cadena de \u00e1cido graso diac\u00eddico C18 unida mediante un enlazador en la posici\u00f3n 26 \u2014 la caracter\u00edstica responsable de la uni\u00f3n a la alb\u00famina y la vida media plasm\u00e1tica prolongada. F\u00f3rmula molecular: C\u2081\u2088\u2084H\u2082\u2089\u2081N\u2084\u2085O\u2085\u2089. Peso molecular: aproximadamente 4,113.58 Da. N\u00famero CAS: 910463-68-2.<\/p>\n<h2>Investigaci\u00f3n destacada<\/h2>\n<p>La actividad agonista del receptor GLP-1 de la semaglutida ha sido examinada en investigaciones precl\u00ednicas publicadas en modelos metab\u00f3licos, cardiovasculares y neurol\u00f3gicos. La investigaci\u00f3n metab\u00f3lica ha estudiado la secreci\u00f3n de insulina por c\u00e9lulas beta pancre\u00e1ticas, la inhibici\u00f3n de la producci\u00f3n hep\u00e1tica de glucosa y la regulaci\u00f3n de la lip\u00f3lisis en tejido adiposo en modelos animales in vivo. Los estudios sobre la tasa de vaciamiento g\u00e1strico y las v\u00edas de se\u00f1alizaci\u00f3n de saciedad han sido documentados en m\u00faltiples publicaciones con modelos en roedores. La investigaci\u00f3n cardiovascular ha examinado los efectos sobre marcadores de placa ateroscler\u00f3tica, mediadores inflamatorios card\u00edacos y par\u00e1metros de funci\u00f3n endotelial vascular en modelos precl\u00ednicos. La investigaci\u00f3n neurol\u00f3gica ha explorado la expresi\u00f3n del receptor GLP-1 en el sistema nervioso central, incluyendo la influencia de la semaglutida sobre los circuitos dopamin\u00e9rgicos, marcadores de neuroinflamaci\u00f3n y v\u00edas relacionadas con el amiloide en modelos en roedores. Investigaciones publicadas adicionales han examinado marcadores de fibrosis hep\u00e1tica en modelos en roedores de NASH y la modulaci\u00f3n del perfil de citocinas (TNF-alfa, IL-6, IL-1beta) en modelos de inflamaci\u00f3n sist\u00e9mica.<\/p>\n<h2>Principales aplicaciones de investigaci\u00f3n<\/h2>\n<ul>\n<li>Modelado de la v\u00eda de se\u00f1alizaci\u00f3n del receptor GLP-1 y la secreci\u00f3n de insulina en cascada<\/li>\n<li>Estudios de supresi\u00f3n de la producci\u00f3n hep\u00e1tica de glucosa y gluconeog\u00e9nesis<\/li>\n<li>Investigaci\u00f3n de lip\u00f3lisis en tejido adiposo, gasto energ\u00e9tico y composici\u00f3n corporal<\/li>\n<li>Investigaciones sobre la tasa de vaciamiento g\u00e1strico y la motilidad gastrointestinal<\/li>\n<li>Investigaci\u00f3n sobre modulaci\u00f3n de marcadores de riesgo cardiovascular y funci\u00f3n endotelial<\/li>\n<li>Estudios de expresi\u00f3n del receptor GLP-1 en el sistema nervioso central y circuitos dopamin\u00e9rgicos<\/li>\n<li>Investigaci\u00f3n de neuroinflamaci\u00f3n y v\u00edas del amiloide en modelos en roedores<\/li>\n<li>Investigaci\u00f3n sobre modulaci\u00f3n del perfil de citocinas antiinflamatorias<\/li>\n<li>Estudios de marcadores de NASH, esteatosis hep\u00e1tica y fibrosis hep\u00e1tica<\/li>\n<li>Farmacolog\u00eda comparativa de agonistas del receptor GLP-1 (frente a liraglutida, dulaglutida)<\/li>\n<\/ul>\n<p><em>Solo para uso en investigaci\u00f3n de laboratorio. No est\u00e1 destinado a uso humano ni veterinario, diagn\u00f3stico m\u00e9dico, tratamiento ni prevenci\u00f3n de ninguna enfermedad o afecci\u00f3n. Este producto no ha sido evaluado por la FDA ni por ning\u00fan organismo regulador. Debe ser manejado por personal de investigaci\u00f3n calificado en un entorno de laboratorio que cumpla con la normativa aplicable.<\/em><\/p>\n<p style=\"margin-top:20px;padding:14px 18px;background:#f0f6fa;border-left:4px solid #c9a44d;border-radius:0 4px 4px 0;font-size:0.9rem;line-height:1.5\">\u00bfNo sabes qu\u00e9 compuestos se ajustan a tu investigaci\u00f3n? <a href=\"https:\/\/portaltowellness.net\/research\/\" style=\"color:#0c2b3a;font-weight:700;text-decoration:none\">Explora el Centro de Investigaci\u00f3n \u2192<\/a><\/p>\n<div class=\"ptw-faq-block\">\n<h2>Preguntas frecuentes \u2014 Semaglutida<\/h2>\n<h3>\u00bfEn qu\u00e9 se diferencia la semaglutida de otros p\u00e9ptidos GLP-1 como la tirzepatida?<\/h3>\n<p>La semaglutida es un agonista del receptor GLP-1. La tirzepatida es un agonista dual de los receptores GIP y GLP-1. Ambas mol\u00e9culas han sido estudiadas en ensayos cl\u00ednicos que utilizaron material de grado farmac\u00e9utico bajo supervisi\u00f3n m\u00e9dica; esos ensayos constituyen informaci\u00f3n de referencia sobre las mol\u00e9culas, no una descripci\u00f3n de este producto.<\/p>\n<h3>\u00bfQu\u00e9 est\u00e1ndar de pureza aplica a esta semaglutida?<\/h3>\n<p>La especificaci\u00f3n del proveedor es \u226598% de pureza. Portal to Wellness la suministra exclusivamente para uso en investigaci\u00f3n de laboratorio.<\/p>\n<h3>Investigaci\u00f3n relacionada (educativa)<\/h3>\n<ul>\n<li><a href=\"\/research\/body-recomposition-glp1-research\/\">Recomposici\u00f3n corporal con p\u00e9ptidos GLP-1: lo que muestra la investigaci\u00f3n<\/a><\/li>\n<li><a href=\"\/research\/muscle-preservation-caloric-restriction-research\/\">Preservaci\u00f3n muscular durante la restricci\u00f3n cal\u00f3rica: perspectivas de compuestos de investigaci\u00f3n<\/a><\/li>\n<li><a href=\"\/research\/visceral-fat-metabolic-health-research\/\">Grasa visceral y salud metab\u00f3lica: lo que los investigadores est\u00e1n estudiando<\/a><\/li>\n<\/ul>\n<div class=\"ptw-research-library\" style=\"background:#f8f9fa;border-left:3px solid #2e7d32;padding:16px 20px;margin-top:24px;border-radius:4px\">\n<p style=\"margin:0 0 8px;font-weight:600;font-size:14px;text-transform:uppercase;letter-spacing:.05em;color:#2e7d32\">Biblioteca de investigaci\u00f3n<\/p>\n<ul style=\"margin:0;padding-left:20px\">\n<li><a href=\"\/research\/injectable-vs-oral-glp1-what-researchers-need-to-know\/\">GLP-1 inyectable vs. oral: lo que los investigadores necesitan saber<\/a><\/li>\n<li><a href=\"\/research\/glp1-biological-aging-epigenetic-research\/\">Agonistas del receptor GLP-1 y envejecimiento biol\u00f3gico: lo que muestra la investigaci\u00f3n<\/a><\/li>\n<li><a href=\"https:\/\/portaltowellness.net\/research\/semaglutide-biological-aging-epigenetic-clock\/\">Semaglutida y envejecimiento biol\u00f3gico: lo que muestran los datos del reloj epigen\u00e9tico<\/a><\/li>\n<li><a href=\"https:\/\/portaltowellness.net\/research\/preserving-lean-mass-glp-1-semalean-data\/\">Preservaci\u00f3n de masa magra durante la investigaci\u00f3n con GLP-1: lo que mostraron los datos de SEMALEAN<\/a><\/li>\n<li><a href=\"https:\/\/portaltowellness.net\/research\/regulatory-pathway-labels-explained\/\">Etiquetas de v\u00edas regulatorias explicadas: de marca, gen\u00e9rico, compuesto y RUO \u2192<\/a><\/li>\n<li><a href=\"https:\/\/portaltowellness.net\/research\/cagrilintide-semaglutide-redefine-1-trial-data\/\">Datos del ensayo de cagrilintida y semaglutida<\/a><\/li>\n<li><a href=\"https:\/\/portaltowellness.net\/research\/semaglutide-knee-osteoarthritis-research\/\">Semaglutida y osteoartritis de rodilla<\/a><\/li>\n<li><a href=\"https:\/\/portaltowellness.net\/research\/glp-1-frailty-risk-older-adults\/\">Riesgo de fragilidad con GLP-1 en adultos mayores<\/a><\/li>\n<li><a href=\"https:\/\/portaltowellness.net\/research\/glp-1-dosing-errors-telehealth\/\">Errores de dosificaci\u00f3n con GLP-1: datos de telesalud<\/a><\/li>\n<li><a href=\"https:\/\/portaltowellness.net\/research\/what-determines-regulatory-status\/\">Qu\u00e9 determina el estatus regulatorio<\/a><\/li>\n<li><a href=\"https:\/\/portaltowellness.net\/research\/glp-1-eating-disorder-risk\/\">GLP-1 y riesgo de trastornos alimentarios<\/a><\/li>\n<li><a href=\"https:\/\/portaltowellness.net\/research\/glp-1-bariatric-surgery-teens\/\">GLP-1 vs. cirug\u00eda bari\u00e1trica en adolescentes: lo que muestran los nuevos datos<\/a><\/li>\n<li><a href=\"https:\/\/portaltowellness.net\/research\/fda-warning-letters-glp1-telehealth-crackdown\/\">Cartas de advertencia de la FDA al marketing de GLP-1 en telesalud: qu\u00e9 significa el endurecimiento regulatorio de 2026<\/a><\/li>\n<li><a href=\"https:\/\/portaltowellness.net\/research\/glp-1-prior-authorization-data\/\">Datos de autorizaci\u00f3n previa para GLP-1<\/a><\/li>\n<li><a href=\"https:\/\/portaltowellness.net\/research\/compounded-peptide-vs-research-peptide\/\">P\u00e9ptido compuesto vs. p\u00e9ptido de investigaci\u00f3n<\/a><\/li>\n<li><a href=\"https:\/\/portaltowellness.net\/research\/biomarkers-vs-clinical-outcomes-research\/\">Biomarcadores vs. resultados cl\u00ednicos en investigaci\u00f3n<\/a><\/li>\n<li><a href=\"https:\/\/portaltowellness.net\/research\/biomarkers-vs-clinical-outcomes-research\/\">Biomarcadores vs. resultados cl\u00ednicos en investigaci\u00f3n<\/a><\/li>\n<li><a href=\"https:\/\/portaltowellness.net\/research\/wegovy-pill-total-monthly-cost\/\">Costo mensual de la p\u00edldora Wegovy, explicado<\/a><\/li>\n<li><a href=\"https:\/\/portaltowellness.net\/research\/glp-1-additives-compounding-study\/\">Aditivos en GLP-1: lo que encontr\u00f3 un nuevo estudio de JAMA<\/a><\/li>\n<li><a href=\"https:\/\/portaltowellness.net\/research\/glp-1-cancer-risk-what-trials-show\/\">Riesgo de c\u00e1ncer con GLP-1: lo que muestran los ensayos<\/a><\/li>\n<li><a href=\"https:\/\/portaltowellness.net\/research\/glp-1-mood-research-what-trials-show\/\">Investigaci\u00f3n sobre el estado de \u00e1nimo y GLP-1: lo que muestran los ensayos<\/a><\/li>\n<li><a href=\"https:\/\/portaltowellness.net\/research\/real-world-glp-1-outcomes-vs-trials\/\">Resultados reales de GLP-1 vs. resultados en ensayos cl\u00ednicos<\/a><\/li>\n<li><a href=\"https:\/\/portaltowellness.net\/research\/glp-1-health-benefits-explained\/\">Agonistas del receptor GLP-1: mecanismos en la literatura<\/a><\/li>\n<\/ul>\n<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>P\u00e9ptido agonista del receptor GLP-1, ampliamente estudiado en investigaci\u00f3n metab\u00f3lica. Solo para uso en investigaci\u00f3n.<\/p>","protected":false},"featured_media":393,"comment_status":"open","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ptw_protocol_fit":"","ptw_why_this":"Acts at hypothalamic and brainstem GLP-1 receptors in the published mechanism literature|Metabolic endpoints are reported across the published trial programme|Cardiovascular endpoints were studied in the SELECT trial (2023)|Extended half-life of approximately seven days, attributed to reversible albumin binding","ptw_coa_url":"","ptw_science_overview":"Semaglutide is a GLP-1 receptor agonist with a C18 fatty diacid side chain that enables reversible albumin binding, extending its half-life to approximately 7 days. It binds GLP-1 receptors in the hypothalamus and brainstem, and is studied for effects on appetite signalling, gastric emptying and glucose-dependent insulin secretion. Sold strictly for laboratory research use; not proven in humans; not FDA-approved.","ptw_science_research":"The SELECT trial (2023) evaluated major adverse cardiovascular events in overweight adults without diabetes. Ongoing trials are evaluating applications in metabolic-associated steatohepatitis (MASH), obstructive sleep apnoea, and neurodegenerative disease. Human evidence for research-grade material is not established.","ptw_science_stack":"The published semaglutide literature is largely single-compound. Comparative pharmacology research has examined how extended-half-life GLP-1 agonists differ from short-acting analogues. Sold for laboratory research use only.","_ptw_batch_number":""},"product_brand":[35],"product_cat":[510,520],"product_tag":[287,429,336,430],"class_list":["post-470","product","type-product","status-publish","has-post-thumbnail","product_brand-portal-to-wellness","product_cat-best-sellers","product_cat-metabolic-research","product_tag-glp-1","product_tag-injectable","product_tag-metabolic","product_tag-research","has-subscription-plans","desktop-align-left","tablet-align-left","mobile-align-left","first","instock","sale","purchasable","product-type-simple"],"_links":{"self":[{"href":"https:\/\/portaltowellness.net\/es\/wp-json\/wp\/v2\/product\/470","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/portaltowellness.net\/es\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/portaltowellness.net\/es\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/portaltowellness.net\/es\/wp-json\/wp\/v2\/comments?post=470"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/portaltowellness.net\/es\/wp-json\/wp\/v2\/media\/393"}],"wp:attachment":[{"href":"https:\/\/portaltowellness.net\/es\/wp-json\/wp\/v2\/media?parent=470"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/portaltowellness.net\/es\/wp-json\/wp\/v2\/product_brand?post=470"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/portaltowellness.net\/es\/wp-json\/wp\/v2\/product_cat?post=470"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/portaltowellness.net\/es\/wp-json\/wp\/v2\/product_tag?post=470"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}